Emyria secures clinical-grade MDMA supply for Aust patients
Released
Released
Announcement PDF
ASX Announcement
13 Feb 2023
Emyria secures clinical-grade MDMA supply for Australian patients
HIGHLIGHTS
Emyria has secured sufficient clinical-grade MDMA to support MDMA-assisted therapy for
over 70 patients after the TGA rescheduling of MDMA comes into effect after July 1st 2023 [1].
Emyria is establishing a network of research-oriented therapists and psychiatrists and is
helping ready their sites and care teams to provide MDMA-assisted therapy - via ethics
approved clinical trials and the Authorised Prescriber pathway - to appropriately diagnosed
patients from July 1st 2023.
Emyria to explore licencing models for specialist groups to access Emyria’s MDMA supply and
care model (EMDMA-001).
Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech that operates
clinical services, has secured a supply of clinical-grade MDMA for an initial cohort of Australian
patients through Canadian manufacturer PharmAla, and facilitated by Mind Medicine
Australia, when the rescheduling of MDMA comes into effect, July 1st 2023.
The procurement of patient-ready, GMP-grade MDMA is highly challenging due to strict
Good Manufacturing Practice standards, US supply quota restrictions [2] and limited global
manufacturers. PharmAla is one of the only companies able to export GMP-grade MDMA.
Emyria intends to make the MDMA available to partner psychiatrists with Authorised
Prescriber status or under ethics-approved clinical trials, and is actively collaborating with
clinical partners to ensure their readiness for MDMA-assisted therapy by supporting clinician
training and data monitoring.
Emyria’s Managing Director, Dr Michael Winlo said: “Emyria has expertise delivering
treatments to patients with substances listed under Schedule 8 and 9 while generating
Real-World Evidence to support care model improvement and novel drug development.
To support its partners to provide MDMA-assisted therapy from July 1st, Emyria has secured a
short-term supply of patient-ready MDMA that can be provided within a comprehensive care
model (EMDMA-001) together with appropriately trained and reputable care providers.
Our approach of participating in care delivery also supports our analogue program.”
1.
2.
https://www.tga.gov.au/sites/default/files/2023-02/notice-of-final-decision-to-amend-or-not-amend-the-cur
rent-poisons-standard-june-2022-acms-38-psilocybine-and-mdma.pdf accessed 05 Feb 2023
https://www.federalregister.gov/documents/2022/12/02/2022-26351/established-aggregate-production-quot
as-for-schedule-i-and-ii-controlled-substances-and-assessment
Emyria ASX Announcement | 13 Feb 2023
1
Australia will be one of the first countries to allow patient access to MDMA-assisted
therapy. Securing a reliable, clinical-grade supply of MDMA poses significant challenges due to
its highly regulated nature, requiring specialised knowledge, licences, and permissions from
regulators and law enforcement. The supply agreement with PharmAla helps ensure Emyria's
clinical partners will be ready to support safe and scalable MDMA-assisted therapy while
complying with TGA restrictions regarding Authorised Prescriber status.
The recent rescheduling of MDMA by the TGA following applications by Mind Medicine
Australia also opens a pathway to registration and reimbursement for Emyria's
MDMA-inspired compounds, which are being developed with the University of Western
Australia for a range of neuropsychiatric disorders.
Emyria is advancing its drug discovery program in Australia and the United States to
identify novel, MDMA-like compounds with therapeutic potential, while collaborating with local
clinical partners to improve patient access and ongoing research.
UPCOMING MILESTONES
CLINICAL PROGRAMS
“direct-to-consumer”
“prescription medicine”
PRE-CLINICAL + THERAPY PROGRAMS
New Drug Discovery
MDMA-assisted therapy
Formulation
optimisation (RX5)
Formulation
optimisation (RX7)
Continuous creation
& screening
Protocol developed
Phase 1 study done
Phase 1
First patent family filed
Clinical partnerships
Phase 3
commencement
Pre-IND (FDA)
US-focused
preclinical program
Real-World Data system
Regulatory submission
Pivotal trials
Metabolic studies
MDMA supply secured
Lead selection
Therapist training
Phase 1 trials
First patient
Global commercial strategy
Global commercial strategy
Commercial strategy Australia
Commercial strategy Europe
Commercial strategy USA
- This release has been approved by the Board of Emyria. -
FOR FURTHER INFORMATION
Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com
Emyria ASX Announcement | 13 Feb 2023
Andrew Williams
Media Relations
+61 (0) 412 614 125
awilliams@emyria.com
Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au
2
ABOUT EMYRIA | emyria.com
Emyria Limited is a clinical drug development and care delivery company focused on accelerating
drug development and improving patient outcomes in neuroscience and mental health via:
●
Drug Development: Multiple, proprietary, Ultra-Pure cannabinoid dose forms suitable for
registration against multiple indications. Emyria’s first dose form, EMD-RX5, is in Phase 3 trials.
●
New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world’s largest
libraries of MDMA-like compounds with partner, the University of Western Australia.
●
Proprietary Real-World Data (RWD): Emyria gathers robust and ethically-sourced data with
patients cared for at Emyria’s own specialist clinical service (Emerald Clinics).
Emyria RWD can help support drug development and care model improvement.
EMYRIA’S INTERACTIVE INVESTOR HUB
Investorhub.emyria.com Interact with Emyria’s announcements and updates by
asking questions and comments, which our team can respond to where possible.
About PharmAla Biotech
PharmAla Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research,
development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was
founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable
clinical trials, and to develop novel drugs in the same class. PharmAla is the first publicly-traded
company to manufacture clinical-grade MDMA. PharmAla’s research and development unit has
completed proof-of-concept research into ALA-002, PharmAla’s lead drug candidate. PharmAla is a
“regulatory first” organization, formed under the principle that true success in the psychedelics
industry will only be achieved through excellent relationships with regulators.
About Mind Medicine Australia
Mind Medicine Australia exists to help alleviate the suffering and suicides caused by mental illness in
Australia through expanding the treatment options available to medical practitioners and their
patients. We are focussed on the availability of safe and effective psychedelic-assisted treatments to
treat a range of mental illnesses supported by clinical data. Mind Medicine Australia is a registered
charity founded by Tania de Jong AM and Peter Hunt AM. We are supporting clinical research and
working towards regulatory-approved and evidence-based psychedelic-assisted therapies. We
operate as a peak body that connects medical practitioners, consumers, academia, government,
industry, regulatory bodies, philanthropists, investors and other stakeholders.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release
about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and
other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors, including: the Company’s ability to
successfully develop its product candidates and timely complete its planned clinical programs and the
Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking
statements included in this press release represents the Company’s views as of the date hereof. The Company
anticipates that subsequent events and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied
upon as representing the Company’s views as of any date subsequent to the date hereof.
Emyria ASX Announcement | 13 Feb 2023
3
Share your feedback
Discover